Get the Stockscreener App
74.00
0.05%
-0.04
After Hours:
75.00
1.00
+1.35%
Ani Pharmaceuticals Inc stock is traded at $74.00, with a volume of 229.80K.
It is down -0.05% in the last 24 hours and down -2.18% over the past month.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
See More
Previous Close:
$74.04
Open:
$74
24h Volume:
229.80K
Relative Volume:
0.63
Market Cap:
$1.70B
Revenue:
$923.71M
Net Income/Loss:
$84.68M
P/E Ratio:
18.77
EPS:
3.9419
Net Cash Flow:
$182.81M
1W Performance:
-2.81%
1M Performance:
-2.18%
6M Performance:
-0.09%
1Y Performance:
-20.75%
1-Day Range:
$73.30
$74.97
1-Week Range:
$73.30
$79.43
52-Week Range:
$69.58
$97.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(609) 759-1810
Address
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
74.00 | 1.70B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.01B | 14.57B | -296.50M | 1.64B | -0.259 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
ANIP5868601 Bond Profile: Coupon and Redemption - TradingView
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Price, News, Quote & History - ca.finance.yahoo.com
ANI Pharmaceuticals: Cortrophin’s Q4 Test, With Generics Funding The Build (NASDAQ:ANIP) - Seeking Alpha
ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance Singapore
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - ca.finance.yahoo.com
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ANI Pharmaceuticals gets FDA approval for generic everolimus - Investing.com
Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating - Investing.com
ANI Pharmaceuticals gets FDA approval for generic everolimus By Investing.com - Investing.com UK
ANI Pharmaceuticals Receives FDA Approval for Generic Everolimus Tablets for Oral Suspension - Quiver Quantitative
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension - GlobeNewswire
Oppenheimer Initiates ANI Pharmaceuticals at Perform With $85 Price Target - Yahoo Finance
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth - Eastern Progress
ANI Pharmaceuticals (ANIP) President & CEO Nikhil Lalwani Sells 5,400 Shares - GuruFocus
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $383,400.00 in Stock - MarketBeat
ANI Pharmaceuticals (ANIP) CEO sells 5,400 shares in pre-set trading plan - Stock Titan
Ani Pharmaceuticals director Thoma sells $71,530 in shares By Investing.com - Investing.com South Africa
ANI Pharmaceuticals (NASDAQ: ANIP) insider lines up $380,000 stock sale for 2026 - Stock Titan
ANI Pharmaceuticals Executive Cook Meredith Sells 500 Shares at $70.79 Each (NASDAQ: ANIP) - Kalkine Media
Squarepoint Ops LLC Sells 37,088 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock By Investing.com - Investing.com Canada
Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock - Investing.com
ANI Pharmaceuticals (ANIP) Insider Sale: SVP, General Counsel & Secretary Meredith Cook Sells 500 Shares - GuruFocus
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $35,395.00 in Stock - MarketBeat
Amundi Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Jeanne Thoma Sells 1,000 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals (NASDAQ: ANIP) director plans $71K share sale - Stock Titan
WINTON GROUP Ltd Takes $4.56 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace - Investing.com
ANIP: Record growth in rare disease and generics, with strong financials and strategic expansion - TradingView
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD By Investing.com - Investing.com Nigeria
ETFs Investing in ANI Pharmaceuticals, Inc. Stocks - TradingView
ANI Pharmaceuticals (NASDAQ:ANIP) Sets New 52-Week LowTime to Sell? - MarketBeat
ANI Pharmaceuticals stock hits 52-week low at 70.03 USD - investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
Legal & General Group Plc Buys Shares of 45,075 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board - Yahoo Finance
ANI Pharmaceuticals to Present at September Investor Conferences - The Manila Times
Corient Private Wealth LP Invests $2.01 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $207,480 in stock - Investing.com Nigeria
ANI Pharmaceuticals (ANIP) SVP & CFO Stephen Carey Sells 2,850 S - GuruFocus
ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares - MarketBeat
79,683 Shares in ANI Pharmaceuticals, Inc. $ANIP Purchased by Jupiter Topco LLC - MarketBeat
ANI Pharmaceuticals (ANIP) CFO sells 2,850 shares in preset trading plan - Stock Titan
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):